Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q2 EPS by 13c, Revenues Miss
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $79.90 -2.56%
EPS Growth %: +4.8%
Financial Fact:
TOTAL OPERATING EXPENSES: 19.38M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: +4.8%
Financial Fact:
TOTAL OPERATING EXPENSES: 19.38M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.26), $0.13 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $32.81 million versus the consensus estimate of $37.7 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Nike names former Pfizer CFO David Denton as new finance chief
- BofA lists top 5 themes driving next $1tn in incremental semi sales
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
